|
The buzz: “One in four health plans now have ‘at least one outcomes-based contract’ with a drug maker, an Avalere Health survey showed.” (Bruce Jaspen)
A distorted reimbursement model has pushed soaring healthcare costs to the top of government budgets around the globe. What to do? Life sciences industry players are experimenting with innovative outcome-based pricing models that align reimbursements with positive outcomes, while improving pricing stability and predictability in the life sciences industry. We will explain this model and discuss alternatives for all stakeholders in the value c
|
